European Companies Search Engine
EU funding (€6,000,000): Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy Hor26 Nov 2019 EU Research and Innovation programme "Horizon"
Overview
Text
Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy
Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), and intellectual disability (ID) are clinically heterogeneous, often co-occur, affect ~15% of the EU population; and are associated with somatic illnesses (e.g. epilepsy, autoimmune and gastrointestinal disease) that lead to a significant increase in morbidity and mortality. For instance in ASD the combination of ID and epilepsy is associated with a reduction in lifespan of ~ 20 years; and an economic cost that is greater than cancer, stroke, or dementia. Yet, the research spend on NDDs is less than 1% of those disorders. Hence, we lack effective new treatments for NDDs and do not understand why they co-occur. There is hope, however. Recent evidence shows that rare genetic variants increasing risk for NDDs are shared, converge on final common pathways (e.g. synaptic plasticity, glutamate and GABA neurotransmission, and excitation/inhibition imbalance), and a key role is likely played by immune dysregulation. CANDY’s innovation is to test, for the first time, if NDDs, and their common mental and somatic multi-morbidity, are caused by a combination(s) of common and rare genetic variants and immune activation acting at different ‘sensitive periods’. Our multi-disciplinary team of world leading academics, patient organizations and SMEs will cost-effectively leverage existing EU-funded studies to 1) identify novel mechanisms underpinning NDDs and their multi-morbidity, 2) develop new strategies for prevention and treatment, 3) deliver novel biomarkers to guide early diagnosis, stratification and/or treatment monitoring, and 4) provide open-access databases, translational test batteries, and tools and targets for valorisation. Together we will transform the landscape for people with NDDs and make possible personalized medicine approaches that target particular mechanisms, in specific subgroups of individuals and at different life stages.
Funded Companies:
| Company name | Funding amount |
| ADD Information Services | €30,000 |
| ARTTIC INNOVATION GmbH | €312,087 |
| Arttic | €37,913 |
| Assistance Publique Hopitaux de Paris | €264,580 |
| Autisme-Europe Aisbl | €30,000 |
| Birkbeck College - University of London | €125,000 |
| Commissariat a L Energie Atomique et aux Energies Alternatives | €500,000 |
| Institut National de la Sante et de la Recherche Medicale | €385,420 |
| Institut Pasteur | €425,000 |
| Karolinska Institutet | €300,000 |
| King's College London | €825,000 |
| Noldus Information Technology B.V. | €200,000 |
| Rijksuniversiteit Groningen | €250,000 |
| Stichting Radboud Universitair Medisch Centrum | €1,615,000 |
| €0.00 | |
| UNIVERSITAET ULM | €150,000 |
| €250,000 | |
| Universiteit Gent | €300,000 |
Source: https://cordis.europa.eu/project/id/847818
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "ADD Information Services - EU funding (€6,000,000): Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
